Opko Health (OPK) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is OPK's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

OPKO Health NASDAQ: OPK reported 16% growth in third-quarter revenue from continuing operations and outlined plans to focus on drug development and pharmaceutical products following its proposed sale of BioReference asse…

OPKO Health, Inc. (OPK) Q3 2026 Earnings Call Transcript…

OPKO Health (OPK) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.03 per share a year ago.…

MIAMI, Nov. 04, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical company, today reports business highlights and financial results for the third quarter ended September 30, 2026.…

MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a multinational biopharmaceutical company, today announced that it will report operating and financial results for the third quarter 2026 o…

KIRYAT GAT, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Biologics Ltd., an OPKO Health company (NASDAQ: OPK), today announced that the first participant has been dosed in a first-in-human Phase 1/2a clinical trial of …

OPK's $722M BioReference asset sale to Labcorp, with a potential $150M earnout, aims to sharpen its biopharma focus and expand access to the 4Kscore Test.…

Labcorp Holdings Inc. (NYSE:LH) stock traded higher Thursday after the company agreed to acquire select assets of BioReference Health from OPKO Health Inc. (NASDAQ:OPK) in a deal worth up to $872 million.…

Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide BURLINGTON, N.C. and MIAMI, Fla.…

Ardent Health (NYSE: ARDT - Get Free Report) and OPKO Health (NASDAQ: OPK - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength…

Shares of OPKO Health, Inc. (NASDAQ: OPK - Get Free Report) have received a consensus recommendation of "Hold" from the six brokerages that are presently covering the company, MarketBeat.com reports. One investment analy…

OPKO Health eyes growth from RAYALDEE, partner revenues and a leaner BioReference, while pipeline and reimbursement risks remain key concerns.…

OPKO Health is gaining on pharmaceutical growth, a broad clinical pipeline, strategic partnerships and fresh non-dilutive financing.…

OPKO Health NASDAQ: OPK outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical program…

HCA Healthcare (NYSE: HCA - Get Free Report) and OPKO Health (NASDAQ: OPK - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of the…

MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, tod…

Connor Clark and Lunn Investment Management Ltd. acquired a new stake in OPKO Health, Inc. (NASDAQ: OPK) in a recent quarter, according to the company in its most recent filing with the SEC. The fund acquired 412,051 sha…

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?…

OPKO Health's growth outlook is supported by RAYALDEE, strategic partnerships, BioReference restructuring and multiple pipeline catalysts.…

OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.…

OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced.…

OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks.…

OPK raises $125 million against mazdutide royalties, gaining non-dilutive capital while retaining longer-term royalty upside.…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

